Gattefossé Accelerates Production Ramp-up at Lufkin Facility

Gattefossé, a provider of specialty ingredients and formulation solutions for the pharmaceutical and personal care industries, successfully validated eight strategic ingredients at its Lufkin, TX facility. Three pharmaceutical excipients and five cosmetic ingredients have now achieved manufacturing equivalency, supporting the company’s strategy to expand regional manufacturing while ensuring consistent quality and reliable supply worldwide. 

Building on the EXCiPACT certification (GMP) for pharmaceutical products, the Lufkin site now manufactures these ingredients according to the same quality, analytical and regulatory standards applied across Gattefossé’s global production network. Each validation is supported by a complete technical equivalence file, including analytical validation, stability data, and regulatory documentation to ensure seamless integration into customers’ development and commercialization programs.

Three pharmaceutical excipients now manufactured in Texas include:

The pharmaceutical portfolio validated at Lufkin includes three flagship lipid excipients that support a wide range of drug delivery technologies.

• Peceol is a lipid vehicle used as a solubilizer for lipophilic active pharmaceutical ingredients in oral and topical formulations.
• Compritol 888 is a lipid excipient widely recognized for modified-release drug delivery and lipid matrix technologies.
• Geleol Mono and Diglycerides NF is a multifunctional lipid excipient used as a lipidic vehicle and modified-release agent in oral, topical and semi-solid dosage forms.

“The validation of our first ingredients at our Lufkin facility is a major achievement for our portfolio. Together, these eight excipients provide formulators with reliable solutions to address today’s formulation challenges. By localizing the production of critical lipid-based excipients, we are directly answering our partners’ need for supply chain resilience and dependable domestic sourcing in an increasingly unpredictable global market,” said Ben Blinder, Chief Operating Officer at Gattefossé USA.